Evidence map›Paper›PMID 40955092›Full record

ArticleFuture medicinal chemistry2025

Hybrid chalcone-pyrazoline derivatives: synthesis and in silico evaluation for anticancer potential.

Purabi Saha, Azra Yasmin, Ritesh Jha, Aarti Passi, Vikramdeep Monga, Shammy Jindal, Kamya Goyal

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Purabi SahaDepartment of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, India.ORCID 0000-0001-5153-7551
Azra YasminDepartment of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, India.ORCID 0009-0009-3552-8415
Ritesh JhaDepartment of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, India.ORCID 0000-0002-1791-3864
Aarti PassiDepartment of Pharmaceutical Analysis, ISF College of Pharmacy, Moga, India.ORCID 0009-0005-6420-8323
Vikramdeep MongaDepartment of Pharmaceutical Sciences and Natural Products, School of Health Sciences, Central University of Punjab, Bathinda, India.ORCID 0000-0003-4004-6241
Shammy JindalDepartment of Pharmaceutics, ISF College of Pharmacy and Research, Moga, India.ORCID 0000-0002-1840-9088
Kamya GoyalDepartment of Pharmaceutical Chemistry and Analysis, ISF College of Pharmacy, Moga, India.ORCID 0000-0002-2677-0922

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThis study aimed to design, synthesize, and evaluate a hybrid chalcone-pyrazoline derivatives as potential anticancer agents targeting B-Raf kinase in lung cancer. MATERIAL &

methodsChalcone-pyrazoline derivatives (

resultCompound

conclusionThe findings identify

Indexed as

Antineoplastic AgentsChalconeChalconesProtein Kinase InhibitorsPyrazolesA549 CellsCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorHumansMolecular Docking SimulationMolecular StructureProto-Oncogene Proteins B-rafStructure-Activity RelationshipAntineoplastic AgentsChalconeChalconesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafPyrazolesanticancerB-Raf kinaseChalconein vitrolung cancermolecular dockingpyrazoline

Identifiers

PMID40955092
PMCPMC12536775

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.